ALLMedicine™ Adrenal Cancer Center
Research & Reviews 52 results
BMC Infectious Diseases; Hatakeyama Y, Nakakubo S et. al.
Oct 16th, 2022 - Listeria monocytogenes is a causative agent of food poisoning and is also known to cause invasive diseases, such as bacteremia, meningitis, and encephalitis, in neonates, elderly and immunocompromised patients. However, the clinical course of a mu...
Journal of Surgical Oncology; Moore MD, Agrusa C et. al.
Aug 24th, 2022 - Incidence of venous thromboembolism (VTE) after adrenalectomy for adrenal cortical carcinoma (ACC) is unknown. Herein, we aim to identify the relative incidence and risk factors of VTE after adrenalectomy for ACC. The American College of Surgeons ...
Endocrine Berruti A, Terzolo M et. al.
Jul 23rd, 2022 - Eighth International Adrenal Cancer Symposium Brescia, Italy, September 30 to October 1-2, 2021.|2022|Berruti A,Terzolo M,Filetti S,|
Journal of Medical Case Reports; Goodkin DA
Jun 21st, 2022 - Adrenocortical carcinoma is a rare, but potentially lethal, malignancy that is usually detected as an incidental finding on abdominal imaging studies or owing to hormonal complications. This report recounts an unusual presentation with leg edema d...
Endocrine Perge P, Nyirő G et. al.
May 14th, 2022 - Almost 10 years have passed since the first attempts of liquid biopsy aimed at the characterisation of tumor cells present in the bloodstream from a regular sample of peripheral blood were performed. Liquid biopsy has been used to characterise tum...
Guidelines 1 results
Annals of Oncology : Official Journal of the European Soc... Berruti A, Baudin E et. al.
Nov 20th, 2012 - Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2012|Berruti A,Baudin E,Gelderblom H,Haak HR,Porpiglia F,|diagnosis,pathology,therapy,diagnosis,secondary,therapy,therapeutic use,therapeutic use,therapeutic...
Clinicaltrials.gov 3 results
Sep 24th, 2019 - Malignant pheochromocytoma/paraganglioma (MPP) and adrenocortical carcinoma (ACC) are two rare cancer entities with a very unfavorable prognosis. The knowledge on these rare cancers improved thanks to the French COMETE ('COrtex, MEdulla Tumors End...
Sep 21st, 2016 - The Firm-ACT trial is the first ever conducted randomized controlled phase III trial in adrenocortical carcinoma (ACC), a rare malignancy with poor prognosis. It will provide results leading to the establishment of an urgently needed gold standard...
Jul 10th, 2013 - OBJECTIVES: Determine the feasibility and efficacy of cisplatin, doxorubicin, and tamoxifen (CAT) in patients with soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or adrenal cancer. Determine the toxicity of this regimen in th...
News 6 results
Apr 14th, 2021 - Excess mortality among people with endogenous Cushing syndrome (CS) has declined in the past 20 years yet remains three times higher than in the general population, new research finds. Among more than 90,000 individuals with endogenous CS, the ove...
Dec 20th, 2020 - Sponsored by the University of Michigan Comprehensive Cancer Center Endocrine Oncology Adrenal Cancer Program, the 5th International Adrenal Cancer Symposium is an exciting combination of science, clinical care and resources for the physician and ...
Jul 29th, 2020 - A strategy that includes a urine steroid test along with imaging characteristics and tumor size criteria can significantly improve the challenging diagnosis of adrenocortical cancer, helping to avoid unnecessary, and often unsuccessful, further im...
Jun 29th, 2019 - PodMed Double T is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center in El Paso, look at the top me...
Sally Koch Kubetin
Feb 2nd, 2017 - The immigration ban from seven Muslim-majority countries issued recently by the Trump administration is having the unintended effect of disrupting scientific collaboration, according to a statement issued by the Endocrine Society. “President Donal.